APA引用形式

Alexandre, M., Bohelay, G., Bohelay, G., Gille, T., Gille, T., Roux-Villet, C. L., . . . Prost-Squarcioni, C. (2022). Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients. Frontiers Media S.A.

シカゴスタイル引用形

Alexandre, Marina, et al. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid With Omalizumab As Add-On Therapy: A Case Series Of 13 Patients. Frontiers Media S.A, 2022.

MLA引用形式

Alexandre, Marina, et al. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid With Omalizumab As Add-On Therapy: A Case Series Of 13 Patients. Frontiers Media S.A, 2022.

警告: この引用は必ずしも正確ではありません.